NovaMedica
| Site | |
|---|---|
| Stage of funding: | Current |
Description
NovaMedica is a Russian specialty pharmaceutical company created in 2012 for the development of innovative medicines in Russia, as a cooperation project between Domain Associates LLC, a leading US venture capital firm it the field of Life Sciences, and RMI LLC, also a Life Scences venture capital firm funded by Rusnano JSC.
NovaMedica’s strategy is aimed at bringing IP rights to innovative products and technologies to Russia, at own development and market launch of new drugs, and at implementation of projects for partners on a contractual basis, including GMP-compliant manufacturing.
NovaMedica owns IP rights to innovative solutions courced from the portfolio companies of RMI LLC. NovaMedica’s pipeline comprises drugs for the treatment of oncological and orphan diseases, including epilepsy, as well as innovative technologies for diagnostics of infectious diseases.
In 2017, NovaMedica opened the R&D Center NovaMedica Innotech, which provides pharmacists and researchers with state-of-the-art technological capacities that were not previously available in the Russian pharma industry.
In the same year, the R&D Center NovaMedica Innotech received from the Russian Ministry of Industry and Trade a manufacturing license and a GMP certificate, which makes it possible to manufacture and release medicinal products, carry out research as part of development of innovative drugs and provide contract-based pharmaceutical production services.
NovaMedica is working to create a whole range of its own products, which are at various stages of development: from dosage form creation to clinical trials, state registration and market launch. Some of these products already have marketing authorizations and are available in the market, and NovaMedica’s first own R&D product became part of the portfolio of the corporation Bayer under a partnership agreement.
NovaMedica is actively developing its CNS product portfolio, building it by means of both own developments and products brought in through licensing deals with various partners. Our company also has a robust and efficient infrastructure for promotion and sales of pharmaceutical products. In this area, NovaMedica’s partner is AstraZeneca.
NovaMedica’s team is formed by top managers with many years of experience in successful implementation of pharmaceutical projects. Team leaders have repeatedly made it to the TOP 1000 Russian Managers List (in 2022, 2021, 2020, 2019, 2018, 2017 and 2016) of the Russian Managers Association and Kommersant Publishing House.
The company is based in Moscow, Russia. More details at: http://novamedica.com
Portfolio companies news
-
Clearside Biomedical, Inc. (“Clearside”), (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that data from PEACHTREE, its pivotal Phase 3 trial of suprachoroidal CLS-TA in patients with macular edema associated with non-infectious uveitis, will be shared as a late-breaking oral presentation during the 2018 annual meeting of the American Society of Retina Specialists , July 20-25 in Vancouver, Canada .
-
11 July 2018
Clearside Biomedical Appoints Carol Hoang as Vice President, Medical Affairs
-
10 July 2018
Blood Test Predicts Treatment Response and Survival for Patients with Metastatic Prostate Cancer
-
21 June 2018
Marinus Pharmaceuticals to Be Added to the Russell 2000 and Russell 3000 Index